OCUL at a glance
OCULAR THERAPEUTIX, INC (OCUL, SEC CIK 1393434) filed its latest 10-K annual report on February 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), OCULAR THERAPEUTIX, INC (OCUL) reported revenue of $52.0 million (down 18.5% from FY2024) and a net loss of $265.9 million. Diluted EPS was -$1.42.
- As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding OCULAR THERAPEUTIX, INC (OCUL) shares worth $464.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Saroj Namrata on November 5, 2026 of 35,370 shares at $6.55 per share.
- In the last 90 days, OCUL insiders reported 0 open-market purchases ($0) and 10 open-market sales ($1.0M) on Form 4, a net sale of $1.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $52.0M
- −18.5% vs prior year
- Insiders · 90 days
- 0 buys · 10 sells
- Net −$1.0M
- 13F holders
- 29 funds
- $464.9M · +0 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Integrated biopharmaceutical company developing ELUTYX hydrogel-based ocular drug delivery platform for retina diseases
- New emphasis on AXPAXLI (OTX-TKI), a Phase 3 axitinib intravitreal hydrogel implant targeting wet AMD and diabetic retinal disease with registrational trials SOL and HELIOS
- Strategic shift: Expansion from commercial DEXTENZA steroid to late-stage novel AXPAXLI candidate with accelerated NDA timeline via 505(b)(2) pathway
- Quantitative highlight: SOL-1 trial randomized 344 subjects by Dec 2024; SOL-R trial randomized 631 subjects by Nov 2025 across US, Argentina, India, Australia
- Noteworthy fact: ELUTYX technology used in 5 million+ patients since 1992; DEXTENZA implanted in nearly 750,000 eyes with adverse events in 0.02% patients
Risk Factors
- Regulatory risk: FDA may require additional trials delaying AXPAXLI approval for wet AMD and diabetic retinal disease
- Macroeconomic exposure: $82.5M debt under Barings Credit Facility requires minimum liquidity $20M, royalty fee 3.5% of DEXTENZA sales
- Operational vulnerability: reliance on scaling manufacturing and commercial capabilities for DEXTENZA and AXPAXLI commercialization
- Competitive risk: uncertainty if AXPAXLI achieves sufficient market acceptance against other treatments for wet AMD and NPDR
- Financial risk: net losses $265.9M in 2025, accumulated deficit $1.157B, may require additional capital raising causing dilution or operational constraints
Management Discussion & Analysis
- Revenue $51.9M in 2025 vs $63.7M in 2024 and $58.4M in 2023, declining due to decreased DEXTENZA sales
- Net loss widened to $265.9M in 2025 from $193.5M in 2024 and $80.7M in 2023; operating expenses $322.0M in 2025
- Operating margin negative, reflecting sustained losses and increasing R&D and commercial expenses
- Cash and cash equivalents $737.1M at Dec 31, 2025; financing activities provided $561.7M in 2025 including $445.6M from 2025 stock offering
- Management expects cash to fund operations into 2028 but anticipates need for additional funds to commercialize AXPAXLI if approved
AI summary of the OCUL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material risk-factor changes disclosed from the December 31, 2025 Form 10-K
- Clinical-development risk: AXPAXLI direct program expenses rose to $119,966 through nine months
- Legal risk: EyePoint litigation settled October 30, 2026 with no financial obligation
- Liquidity risk: $530,612 cash supports planned operations through 12 months while maintaining $20,000 minimum liquidity
- Debt risk: $82,474 Barings principal due in 2029 with SOFR plus 6.75% interest terms
Management Discussion & Analysis
- Quarterly revenue $12.9M, down 11.0% YoY from $14.5M, entirely DEXTENZA product revenue
- Net loss $94.8M vs $69.4M YoY, operating loss $97.9M vs $68.7M
- Worst performer DEXTENZA: revenue down $1.6M, GTN provisions 57.7% vs 52.5%
- Cash and equivalents $530.6M, operating cash use $198.9M for nine months vs $150.6M YoY
- Outlook: NDA submission targeted Q4 2026, cash expected to fund operations into 2028, R&D expenses expected to increase
AI summary of the OCUL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 2026 net revenue $12.9M vs $14.5M; net loss widened to $94.8M, or $0.42/share
- Cash $530.6M supports planned operations into 2028, excluding full manufacturing and commercial scale-up costs
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Riad Sherif, former Novartis and Alcon executive, elected to Class I board seat through 2027 annual meeting
- Ophthalmology industry expertise added through Oculis Holding AG CEO and Revenio Group board member
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Strategy Officer Sanjay Nayak resigning effective October 16, 2026
- Departure to become CEO of a privately held company, indicating loss of senior strategic leadership
AI summaries of OCUL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OCUL
Don't miss the next OCUL filing
- Alerts as it files. A push when OCUL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OCUL, by share count.
- Ask anything. An AI agent that reads every OCUL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sherif Riad | A | Nov 6, 2026 | 28,000 | - |
| Sherif Riad | A | Nov 6, 2026 | 88,000 | - |
| Saroj Namrata | Sell | Nov 5, 2026 | 35,370 | $6.55 |
| Anderman Todd | Sell | Oct 8, 2026 | 11,984 | $7.29 |
| Kaiser Peter | Sell | Oct 2, 2026 | 9,990 | $7.05 |
| Heier Jeffrey S. | Sell | Oct 2, 2026 | 10,869 | $7.05 |
| Notman Donald | Sell | Aug 31, 2026 | 1,099 | $10.24 |
| Dugel Pravin | G | Aug 25, 2026 | 50,092 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $63.7M | $52.0M |
| Operating Income | - | -$171.8M | -$270.0M |
| Net Income | -$80.7M | -$193.5M | -$265.9M |
| Op. Margin | - | -269.6% | -519.8% |
| Net Margin | - | -303.7% | -511.9% |
| Balance Sheet | |||
| Total Assets | $252.1M | $457.9M | $808.1M |
| Equity | - | $315.3M | $654.3M |
| ROE | - | -61.4% | -40.6% |
| Per Share | |||
| EPS | $-1.02 | $-1.22 | $-1.42 |
| Cash Flow | |||
| Operating CF | - | -$134.7M | -$204.9M |
| CapEx | $6.1M | $1.3M | $12.0M |
Source: XBRL data in OCULAR THERAPEUTIX, INC (OCUL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate OCUL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 29 | $464.9M |
| Q2 2026 | 29 | $889.6M |
| Q1 2026 | 30 | $700.9M |
| Q4 2025 | 27 | $979.3M |
| Q3 2025 | 27 | $874.3M |
| Q2 2025 | 28 | $542.2M |
| Q1 2025 | 25 | $198.6M |
| Q4 2024 | 20 | $189.4M |
- Two Sigma Investments+1.21M (+99%)
- BlackRock+598.2K (+3%)
- Invesco Ltd+499.9K (+37%)
- Raymond James Financial+383.1K (+40%)
- State Street Corp+342.2K (+7%)
- T. Rowe Price Group−433.5K (-6%)
- Goldman Sachs Group−218.0K (-12%)
- Morgan Stanley−180.7K (-20%)
- Wells Fargo & Co−97.4K (-42%)
- Citigroup−74.8K (-53%)
- Franklin Resources+11.2K
- Fifth Third Bancorp+295
- FMR LLC (Fidelity)−32.84M
- Allstate−16.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 215 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OCUL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 10, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Nov 9, 2026 | - | - | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
OCUL SEC filings: frequently asked questions
Are OCUL insiders buying or selling?
In the last 90 days, OCULAR THERAPEUTIX, INC (OCUL) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $1.0 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold OCUL stock?
As of September 30, 2026, the largest OCULAR THERAPEUTIX, INC (OCUL) holders among the 13F filers tracked by SignalX were BlackRock ($153.2 million), Vanguard Capital Management LLC ($68.6 million), T. Rowe Price Group ($55.1 million), State Street Corp ($42.8 million), Dimensional Fund Advisors ($22.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OCUL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), OCULAR THERAPEUTIX, INC (OCUL) reported revenue of $52.0 million (down 18.5% from FY2024) and a net loss of $265.9 million. Diluted EPS was -$1.42. The figures come from the XBRL data in the 10-K.
What are the main risks in OCUL's latest 10-K?
In the 10-K filed February 5, 2026, OCULAR THERAPEUTIX, INC (OCUL) flagged: Regulatory risk: FDA may require additional trials delaying AXPAXLI approval for wet AMD and diabetic retinal disease. Macroeconomic exposure: $82.5M debt under Barings Credit Facility requires minimum liquidity $20M, royalty fee 3.5% of DEXTENZA sales. (AI summary of the Risk Factors section.)
What did OCUL report in its latest 8-K?
OCULAR THERAPEUTIX, INC (OCUL) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest OCUL SEC filings?
OCULAR THERAPEUTIX, INC (OCUL) filed its latest 10-K annual report on February 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 10, 2026.
What is OCUL's SEC CIK number?
OCULAR THERAPEUTIX, INC (OCUL)'s SEC Central Index Key (CIK) is 1393434. EDGAR lists every OCUL filing under that number.
Ask anything about OCUL
The research agent reads OCUL's filings, financials, insider trades and 13F holders, then answers with sources.